[细胞癌的辅助疗法:相关的患者和瘤因素]
1Klinik für Urologie & Transplantationschirurgie, Eva Mayr-Stihl Cancer Center Stuttgart, Klinikum Stuttgart, Kriegsbergstraße 60, 70191, Stuttgart, Deutschland. bedke@live.com.
使用 pembrolizumab 的辅助免疫疗法在减少手术后细胞癌复发方面显示出有前途. 损伤分子-1 (KIM-1) 可能成为未来预测治疗反应的生物标志物.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
